LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akciju saraksts・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Slēgts

4.73 0.64

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.66

Max

4.79

Galvenie mērījumi
By Trading Economics
Ienākumi	-10M -7.7M
Pārdošana	-10M 529K
EPS	-0.056
Peļņas marža	-1,463.516
Darbinieki	44
EBITDA	-10M -7.7M

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11M 869M
Iepriekšējā atvēršanas cena	4.09
Iepriekšējā slēgšanas cena	4.73

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

3.255 / 3.365 Atbalsts un pretestība

Arbutus Biopharma Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. dec. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025. g. 13. dec. 00:04 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025. g. 14. dec. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025. g. 14. dec. 23:36 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 14. dec. 22:38 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025. g. 14. dec. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025. g. 14. dec. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Acquire Remaining 64% of Alta Copper

2025. g. 14. dec. 17:00 UTC

Peļņas

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025. g. 14. dec. 08:30 UTC

Iegādes, apvienošanās, pārņemšana

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025. g. 13. dec. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 08:00 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 07:00 UTC

Iegādes, apvienošanās, pārņemšana

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025. g. 13. dec. 00:24 UTC

Iegādes, apvienošanās, pārņemšana

Want a Piece Of SpaceX? -- Barrons.com

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Salīdzinājums

Cenas izmaiņa

Arbutus Biopharma Corp Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arbutus Biopharma Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.255 / 3.365Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.